Key Takeaways PBYI stock jumped 29.6% in three months, far outpacing its industry, sector and the S&P 500.Nerlynx sales grew 9% in H1 2025 to $92.3M. Full-year sales are guided to be in the range of $192-$198M.Initial phase II data on alisertib for lung cancer and breast cancer are expected in Q4 2025.Puma Biotechnology (PBYI) stock delivered a solid performance in the past three months, with its shares rallying 29.6% compared with the industry’s rise of 3.9%. The stock has also outperformed the sector and ...